본문 바로가기

Hanmi's New Story

힘차게 도약하는 한미
함께하는 미래

한미약품의 새로운 이야기가 펼쳐집니다.

The Hanmi Way

No path started as a path.
We seek a better future for humanity on it.

View More
main3 main3

Innovation

Korea's leading R&D-centric healthcare company.
We create never-before-seen innovation through bold challenges.

asdfa asdf

Respect, Trust, Integrity

We lead the global healthcare industry
through Respect, Trust, and Integrity.

Focus on Making
Innovative Medicines

한미약품은 다양한 치료 영역을 포괄하는
탄탄한 R&D 인프라를 바탕으로
제약분야에서 혁신을 선도하고 있습니다.

비만/대사

비만, 대사 이상 관련 지방간염 등 다양한 작용기전
Best-in-class 신약 개발

View More

What We Make

ESG Report

한미약품의 ESG 경영은
'일상의 혁신'입니다.

View More

당신의 꿈이
한미약품의 미래입니다.
당신을 기다립니다.

Join Us
Meet Us at American Diabetes Association
(ADA) 2024 Scientific Sessions.

Meet Us at American Diabetes Association (ADA) 2024 Scientific Sessions.

Therapeutic potential of HM15275, a novel long-acting GLP-1/GIP/GCG triple agonist, in animal models of heart failure
Abstract Number
1872-LB
Session
12-B Clinical Therapeutics-Incretin-Based Therapies (Poster), Jun 22 at 12:30 PM ~ 1:30 PM ET, Poster Hall (West A4-B2)
Presenter
Byeong Jin Ye, Ph.D. /
Hanmi Pharmaceutical

byeongjin.ye@hanmi.co.kr

Potent weight loss and favorable glycemic control effects of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in animal models
Abstract Number
776-P
Session
12-B Clinical Therapeutics-Incretin-Based Therapies (Poster), Jun 23 at 12:30 PM ~ 1:30 PM ET, Poster Hall (West A4-B2)
Presenter
Sang Hyun Park, Ph.D. /
Hanmi Pharmaceutical

sanghyun.park@hanmi.co.kr

Potential cardioprotective effects of HM15275, a novel, long-acting GLP-1/GIP/GCG triple agonist, in animal models of hypertension
Abstract Number
798-P
Session
12-B Clinical Therapeutics-Incretin-Based Therapies (Poster), Jun 23 at 12:30 PM ~ 1:30 PM ET, Poster Hall (West A4-B2)
Presenter
Seon Myeong Lee /
Hanmi Pharmaceutical

seonmyeong.lee@hanmi.co.kr

Nephroprotective effects of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in preclinical models of acute and chronic kidney diseases
Abstract Number
799-P
Session
12-B Clinical Therapeutics-Incretin-Based Therapies (Poster), Jun 23 at 12:30 PM ~ 1:30 PM ET, Poster Hall (West A4-B2)
Presenter
Seon Myeong Lee /
Hanmi Pharmaceutical

seonmyeong.lee@hanmi.co.kr